PDLIM1

Across TCGA pan-cancer cohorts, PDLIM1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PDLIM1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PDLIM1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDLIM1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

OV, UCEC, and STAD are the cancer types where PDLIM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.028	0.844	<.001	48	view →
UCEC	DFS	Median	All	1.000	0.619	.008	16	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PDLIM1–OV (OS)

Open the OV breakdown →